Related Experiment Video

Updated: May 18, 2026

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

CD30 in myeloid malignancies: hitting the bull's-eye with an available dart

Ashkan Emadi1, Judith E Karp

  • 1University of Maryland, School of Medicine, Marlene & Stewart Greenebaum Cancer Center, Leukemia & Hematologic Malignancies, Baltimore, MD, USA. aemadi@umm.edu

Leukemia & Lymphoma
|September 13, 2012
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling
07:51

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling

Published on: March 20, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Experiment Videos

Last Updated: May 18, 2026

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling
07:51

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling

Published on: March 20, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

A systematic review of artificial intelligence in radiotherapy associated cardiovascular toxicity.

Cardio-oncology (London, England)·2026

A Qualitative Analysis of Cancer Survivors' Experience in a Time-Restricted Eating vs Control Clinical Trial to Address Cancer-Related Fatigue.

Seminars in oncology nursing·2026

Artificial Intelligence and Machine Learning in Sexual Health and Dysfunction Across the Cancer Care Continuum: A Systematic Review.

Cancers·2025

Time-restricted eating to address persistent cancer-related fatigue among cancer survivors: a randomized controlled trial.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025

Time-restricted eating to address persistent cancer-related fatigue among cancer survivors: A randomized controlled trial.

Research square·2025

Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia.

International journal of molecular sciences·2024

MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma.

Leukemia & lymphoma·2026

Revisiting invasive fungal infections in acute lymphoblastic leukemia: a systematic review and meta-analysis.

Leukemia & lymphoma·2026

Hypereosinophilic syndrome and suspected myeloid neoplasia in relapsed Hodgkin lymphoma during immune checkpoint inhibitor therapy: a rare case.

Leukemia & lymphoma·2026

CD74 in hematological malignancies: from MHC chaperone to therapeutic target.

Leukemia & lymphoma·2026

Incidence of clinically significant chemotherapy induced nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis.

Leukemia & lymphoma·2026

The roles of RUNX1 in megakaryocyte differentiation in myeloid leukemia.

Leukemia & lymphoma·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us